Study 2 of 26Orforglipron (LY-3502970) literatureLancet (London, England) · Phase 3Top journal2026
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus8
Preclinical · this one
6
Observational
1
Open-label
5
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
AEfficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.BMC endocrine disorders · 2026 · n=3459 · Percentage body weight change p < 0.00001.reviewAPredicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.Diabetes, obesity & metabolism · 2026 · -48.6% to -59.4% relative reduction in T2D risk score vs placebo (-10.5%; p<0.0001; HR-range 0.43-0.55)HumanDOrforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.American journal of nephrology · Not reported in abstract.reviewBExploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023 · For a representative 50-year-old man with T2D, the PCE estimated a 10-year RRR of 16.8% at the 36 mg dose, while PREVENT projected an RRR of 31.4% at the same dose.reviewCVariant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.International journal of biological macromolecules · 2026 · G168S exhibited the strongest binding (-117.18 kcal/mol)In vitroBEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2024 · n=25816 · -12.4% placebo-subtracted weight loss for orforglipron (95% CI, -15.1% to -9.7%)review